

## **REMARKS**

### **Amendments to the Claims**

Claims 1-3, 6, 8-12, and 16 have been amended. Claims 4-5, 7, 13-15, and 18-25 have been withdrawn as drawn to a non-elected invention. Claim 17 has been canceled without prejudice or disclaimer.

Claims 1 and 16 have been amended to clarify the subject matter which Applicants view as the invention and to correct matters of formality. Support for the amendments is found throughout the specification and in the original claims. Claims 2-3, 6, and 8-12 have been amended merely to correct matters of formality.

The claim amendments are made solely in an effort to advance prosecution and are made without prejudice, without intent to acquiesce in any rejection of record, and without intent to abandon any previously claimed subject matter. No new matter has been added by way of these amendments.

### **Restriction Requirement**

With respect to the restriction requirement, Applicants hereby elect with traverse Group II, allegedly drawn to a method for identifying PTEN/IGF pathway modulating agents using a nucleic acid encoding RANBP2 which can further comprise a second assay system comprising cultured cells for prosecution on the merits. The claims readable thereon are claims 1-3, 6, 8-12 and 16.

### **Conclusion**

If the Examiner has any questions regarding this response, she is invited to call the undersigned attorney.

Respectfully submitted,

Dated: September 25, 2008

/Anita J. Terpstra/

Anita J. Terpstra, Ph.D.  
Registration No. 47,132

McDonnell, Boehnen, Hulbert & Berghoff LLP  
300 S. Wacker Drive  
Chicago, IL 60606  
(312) 913-0001